Abstract
Background: Alzheimer's disease (AD) stands out as one of the most devastating and prevalent neurodegenerative disorders known today. Researchers have identified several enzymatic targets associated with AD among which Glycogen synthase kinase-3β (GSK-3β) and Acetylcholinesterase (AChE) are prominent ones. Unfortunately, the market offers very few drugs for treating or managing AD, and none have shown significant efficacy against it.
Objectives: To address this critical issue, the design and discovery of dual inhibitors will represent a potential breakthrough in the fight against AD. In the pursuit of designing novel dual inhibitors, we explored molecular docking and dynamics analyses of tacrine and amantadine uredio-linked amide analogs such as GSK-3β and AChE dual inhibitors for curtailing AD. Tacrine and adamantine are the FDA-approved drugs that were structurally modified to design and develop novel drug candidates that may demonstrate concurrently dual selectivity towards GSK-3β and AChE.
Methods: In the following study, molecular docking was executed by employing AutoDock Vina, and molecular dynamics and ADMET predictions were made using Desmond, Qikprop modules of Schrödinger.
Results: Our findings revealed that compounds DST2 and DST11 exhibited remarkable molecular interactions with active sites of GSK-3β and AChE, respectively. These compounds effectively interacted with key amino acids, namely Lys85, Val135, Asp200, and Phe295, resulting in highly favourable docking energies of -9.7 and -12.7 kcal/mol. Furthermore, through molecular dynamics simulations spanning a trajectory of 100 ns, we confirmed the stability of ligands DST2 and DST11 within the active cavities of GSK-3β and AChE. The compounds exhibiting the most promising docking results also demonstrated excellent ADMET profiles. Notably, DST21 displayed an outstanding human oral absorption rate of 76.358%, surpassing the absorption rates of other molecules.
Conclusion: Overall, our in-silico studies revealed that the designed molecules showed potential as novel anti-Alzheimer agents capable of inhibiting both GSK-3β and AChE simultaneously. So, in the future, the designing and development of dual inhibitors will harbinger a new era of drug design in AD treatment.
Keywords: Alzheimer’s disease, Molecular docking, Molecular dynamics, GSK-3β, AChE, Donepezil.
[http://dx.doi.org/10.3390/molecules25245789] [PMID: 33302541]
[http://dx.doi.org/10.1016/j.pharep.2014.09.004] [PMID: 25712639]
[http://dx.doi.org/10.1007/s00775-010-0699-x] [PMID: 20821241]
[http://dx.doi.org/10.1038/s41598-020-75020-w] [PMID: 33110096]
[http://dx.doi.org/10.3389/fncel.2020.00019] [PMID: 32256316]
[http://dx.doi.org/10.1021/acsmedchemlett.7b00463] [PMID: 29541355]
[http://dx.doi.org/10.1016/j.bmc.2020.115940] [PMID: 33340937]
[http://dx.doi.org/10.1080/14756366.2016.1210139] [PMID: 28133981]
[http://dx.doi.org/10.1002/jcc.21334] [PMID: 19499576]
[http://dx.doi.org/10.1016/j.bmcl.2015.03.046] [PMID: 25845281]
[http://dx.doi.org/10.1021/jm300871x] [PMID: 23035744]
[http://dx.doi.org/10.1016/j.jphotobiol.2017.09.010] [PMID: 28964888]
[http://dx.doi.org/10.1080/07391102.2020.1861982] [PMID: 33345701]
[http://dx.doi.org/10.1080/07391102.2018.1508371] [PMID: 30526410]
[http://dx.doi.org/10.1021/acsomega.8b01524] [PMID: 30320260]
[http://dx.doi.org/10.1111/cbdd.12555] [PMID: 25763767]
[http://dx.doi.org/10.3390/v15071501] [PMID: 37515188]
[http://dx.doi.org/10.1186/2193-1801-2-353] [PMID: 23961417]
[http://dx.doi.org/10.1016/S0092-8674(01)00374-9] [PMID: 11440715]
[http://dx.doi.org/10.1038/s41598-017-09239-5] [PMID: 28819213]
[http://dx.doi.org/10.3390/molecules22081324] [PMID: 28796192]
[http://dx.doi.org/10.1016/j.cbi.2010.01.042] [PMID: 20138030]
[http://dx.doi.org/10.1016/j.cbi.2019.06.011] [PMID: 31176713]
[http://dx.doi.org/10.1111/jnc.13992] [PMID: 28503857]
